Real-world treatment utilization patterns, discontinuation and healthcare resource utilization of first-line (1L) bruton tyrosine kinase inhibitor (BTKi) therapy in chronic lymphocytic leukemia (CLL): Age-related disparity.

Authors: Keri Yang, Swetha Challagulla, Po-Ya Chuang, Wesley Furnback, Sikander Ailawadhi

Published: 2025-05-28

DOI: 10.1200/jco.2025.43.16_suppl.e19033

Source: Full article

e19033